Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications
It can be used for everyday nutritional support, for periods of increased oxidative stress and targeted cleansing, and can be incorporated into individualized endocrine, cardiovascular, or cellular support protocols.* Detoxication Factors - Phase 1 and Phase 2 Detoxication Support Liver detoxication occurs in two phases
the pH value of NAC was adjusted to 7.4 using NaOH
10.1136/bmjopen-2021-060668 111
Int J Alzheimers Dis 2011(1):479249